



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/245, C12N 15/52		A2	(11) International Publication Number: WO 98/04286																																													
			(43) International Publication Date: 5 February 1998 (05.02.98)																																													
(21) International Application Number: PCT/US97/14192		(74) Agents: BENNETT, Dennis, A. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).																																														
(22) International Filing Date: 25 July 1997 (25.07.97)																																																
(30) Priority Data: 08/687,820 26 July 1996 (26.07.96) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).																																														
(60) Parent Application or Grant (63) Related by Continuation US 08/687,820 (CON) Filed on 26 July 1996 (26.07.96)		Published <i>Without international search report and to be republished upon receipt of that report.</i>																																														
(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).																																																
(72) Inventors; and (75) Inventors/Applicants (for US only): HIPPENMEYER, Paul, J. [US/US]; 126 Chippenham, St. Louis, MO 63005 (US). RANKIN, Anne, M. [US/US]; 718 Inglestone, Ballwin, MO 63021 (US). LUCKOW, Verne, A. [US/US]; 233 Portico Drive, Chester, MO 63017 (US).																																																
(54) Title: ASSEMBLY-DEFICIENT HERPESVIRUS VACCINE																																																
<table border="1"> <caption>Survival Data from Graph</caption> <thead> <tr> <th>Days</th> <th>HSV-1(17)</th> <th>HSV/UL26/beta-gluc</th> <th>HSV/UL26/res</th> <th>Naive + HSV-1</th> </tr> </thead> <tbody> <tr><td>1</td><td>10</td><td>10</td><td>10</td><td>10</td></tr> <tr><td>5</td><td>10</td><td>10</td><td>10</td><td>10</td></tr> <tr><td>6</td><td>5</td><td>10</td><td>10</td><td>10</td></tr> <tr><td>7</td><td>1</td><td>10</td><td>10</td><td>10</td></tr> <tr><td>22</td><td>1</td><td>10</td><td>10</td><td>10</td></tr> <tr><td>23</td><td>1</td><td>9</td><td>9</td><td>9</td></tr> <tr><td>38</td><td>1</td><td>5</td><td>5</td><td>5</td></tr> <tr><td>44</td><td>1</td><td>5</td><td>5</td><td>5</td></tr> </tbody> </table>				Days	HSV-1(17)	HSV/UL26/beta-gluc	HSV/UL26/res	Naive + HSV-1	1	10	10	10	10	5	10	10	10	10	6	5	10	10	10	7	1	10	10	10	22	1	10	10	10	23	1	9	9	9	38	1	5	5	5	44	1	5	5	5
Days	HSV-1(17)	HSV/UL26/beta-gluc	HSV/UL26/res	Naive + HSV-1																																												
1	10	10	10	10																																												
5	10	10	10	10																																												
6	5	10	10	10																																												
7	1	10	10	10																																												
22	1	10	10	10																																												
23	1	9	9	9																																												
38	1	5	5	5																																												
44	1	5	5	5																																												
(57) Abstract																																																
<p>A vaccine is described which comprises an assembly-deficient herpesvirus. The mutant herpesvirus is capable of infecting and undergoing DNA replication in the cells of a susceptible mammal, but is defective in capsid assembly and formation of mature virion particles. The assembly-deficient herpesvirus is avirulent and capable of generating a protective immune response in a vaccinated mammal.</p>																																																

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ASSEMBLY-DEFICIENT HERPESVIRUS VACCINE

FIELD OF THE INVENTION

5 This invention is in the field of viral vaccines, and
specifically relates to the generation of assembly-
deficient mutant herpesviruses, vaccines comprising
assembly-deficient mutant herpesviruses, and methods for
the production and manufacture of assembly-deficient
10 herpesvirus vaccines.

BACKGROUND OF THE INVENTION

 There is a great need for therapies for the treatment
15 of viral diseases. While antiviral drugs such as
zidovudine, used in the treatment of human immunodeficiency
virus (HIV), and drugs such as ganciclovir, acyclovir, and
foscarnet are used in the treatment of herpesvirus
infections, significant side effects often limit their
20 effectiveness. The selection and spread of drug-resistant
viruses also limits the effectiveness of small molecular
weight antiviral drugs. This is a particularly significant
problem for drugs targeted against RNA viruses such as HIV,
which have a relatively high mutation rate compared to most
25 DNA viruses.

 Antiviral vaccines are a viable alternative to
postinfection antiviral drug treatments. Ideally,
antiviral vaccines protect against primary disease and
recurring infections. Efficacy against a particular
30 disease is crucial to the development of a vaccine
strategy. Regulatory concerns, particularly related to the
safety of vaccines intended for prophylactic use in healthy
individuals, must also be considered.

 While herpesvirus vaccines have been an active area of
35 both academic and commercial interest, induction of a good,

protective immune response in humans has been challenging [R. L. Burke, *Current Status of HSV Vaccine Development*, in *The Human Herpesviruses*, 367-379, (B. Roizman, R. J. Whitley and C. Lopez, eds. 1993)]. Live virus vaccines
5 have the risk of establishing latency and reactivating. Live virus vaccines also have the potential of recombining with natural isolates.

Attenuated recombinant viruses and subunit vaccines have been investigated to avoid these risks. Meignier et
10 al describe a recombinant virus resulting from the removal of a region of herpes simplex virus type 1 (HSV-1) required for virulence and the insertion of herpes simplex virus type 2 (HSV-2) glycoprotein genes [J. Infect. Dis.,
158:602-614 (1988)]. The viruses had reduced pathogenicity
15 and induced immunity in a number of animal models.

More recently, recombinant herpes simplex viruses with deletions in essential immediate early or early genes have been described. These recombinant viruses are described as
20 being efficacious in inducing immunity and reducing acute replication and establishment of latency of the challenged wild-type virus in mice. Nguyen et al describe
replication-defective mutants of HSV-1 that have mutations in the essential genes encoding infected cell protein 8 ("ICP8") or ICP27 [J. Virol. 66:7067-7072 (1992)]. The
25 ICP8 mutant (Δ 301) expresses the products of the α and β genes while the ICP27 mutant (Δ 504) expresses the products of the α , β , and γ_1 genes in the cells that the viruses can infect. Both viruses induced antibody responses that were
lower than parental (KOS 1.1) virus, but the level induced
30 by the ICP27 mutant was higher than that induced by infection with the ICP8 mutant. Morrison and Knipe later demonstrated that injection of these viruses protected mice against development of encephalitis and keratitis, and decreased the primary replication of virulent challenge

virus [J. Virol. 68:689-696 (1994)]. WO95/18852 describes similar replication-defective herpesvirus mutants and WO94/03207 describes vaccines based on these mutants.

Another recombinant virus has been described that has
5 a deletion in the glycoprotein H (gH) coding region [Forrester et al, J. Virol. 66:341-348 (1992); WO92/05263]. This virus forms virions after infection of non-helper cells, but the viruses fail to infect in a subsequent round. Inoculation of mice with the gH deletion
10 virus resulted in a more rapid clearance of the wild-type challenge virus compared to vaccination with chemically-inactivated virus [Farrell et al, J. Virol. 68:927-932 (1994)]. Inoculation of guinea pigs with the gH deleted recombinant virus resulted in reduced primary vaginal
15 disease and reduced recurrences [McLean et al, J. Infect. Dis. 170:1100-1109 (1994)].

Most viruses encode proteinases that function in the processing of viral proteins during infection [W. G. Dougherty and B. L. Semler, Microbiological Reviews,
20 57:781-822 (1993)]. Biological and biochemical studies have shown that HSV-1 possesses a proteinase that can process another viral protein, the capsid assembly protein (also known as p40, ICP35 and VP22a). Similar proteinases are encoded in the genome of other members of the
25 Herpesviridae. This family of DNA viruses includes HSV-1, HSV-2, human and simian cytomegalovirus (HCMV, SCMV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), human herpesvirus types -6, -7, and -8 (HHV-6, HHV-7, and HHV-8), pseudorabies virus (PRV), bovine herpesvirus (BHV),
30 equine herpesvirus (EHV), and rhinotracheitis virus, among others.

Early work by Preston et al, [J. Virol. 45:1056-1064 (1983)] showed that a temperature-sensitive (ts) mutant in HSV-1 (ts1201) failed to cleave the capsid assembly protein
35 to its lower molecular weight forms at the nonpermissive

temperature. This mutant also failed to package viral DNA. By marker rescue, the defect was mapped to a region of the genome in what is now known as the UL26 open reading frame (ORF) [McGeoch et al, J. Gen. Virol. 69:1531-1574 (1988)].

5 Subsequent analysis showed that two transcripts initiate in the UL26 region, a primary transcript of about 2.1 kb which encodes a protein of 635 amino acids, and a more abundant transcript which is initiated within the UL26 ORF, about 1000 nucleotides 3' of the primary transcript initiation.

10 This smaller transcript encodes a predicted protein of 329 amino acids and is 3' coterminal with the larger 80 kDa ORF encoded by the larger transcript [F. Y. Liu and B. Roizman. J. Virol. 65:206-212 (1991)]. The defect in the ts1201 mutant maps in the 5' region of the longer transcript which

15 has been shown to encode a proteinase activity in HSV-1 [F. Y. Liu and B. Roizman. J. Virol. 65:5149-5156 (1991)] or in simian cytomegalovirus [Welch et al, Proc. Natl. Acad. Sci. USA. 88:10792-10796 (1991)].

Superinfection/transient expression [F. Y. Liu and B. Roizman. J. Virol. 65:5149-5156 (1991)], transient

20 expression [Welch et al, Proc. Natl. Acad. Sci. USA. 88:10792-10796 (1991)], and infection [Preston et al, Virol. 186:87-98 (1992)] studies with the protease domain and the capsid assembly protein domain showed that the

25 proteinase cleaves the capsid assembly protein near its carboxyl terminus. Further studies with the proteins produced in *E. coli* confirmed that the full-length protein of the UL26 ORF is capable of cleaving itself at two sites as well as cleaving the capsid assembly protein [Deckman et

30 al, J. Virol. 66:7362-7367 (1992)]. DiIanni et al later located the cleavage sites between amino acids 247/248 and 610/611 of the UL26 ORF [J. Biol. Chem. 268:2048-2051 (1993)].

Although the results with ts1201 suggest that the

35 defect in the virus is in its ability to cleave the capsid

assembly protein and subsequent encapsidation of DNA, it is not known whether this phenotype is the result of a defect in the protease activity *per se*, or whether the 5' region of the UL26 ORF encodes some other functions required for capsid assembly and maturation. The processed proteinase domain of the 80 kDa precursor (designated as "VP24" or "N₀") has been identified in B-capsids [Davison et al, J. Gen. Virol. 73:2709-2713 (1992)] and is retained in A-capsids and C-capsids [F. J. Rixon, *Structure and Assembly of Herpesviruses*, in *Seminars in Virology*, vol. 4, 135-144, (A. J. Davison, ed. 1993)] suggesting a structural role for this domain. B-capsids are immature capsids in the nucleus of the infected cell that contain the capsid assembly protein, but not viral DNA. These capsids are thought to be the precursors of A-capsids which fail to package DNA and C-capsids which package DNA with concomitant loss of the capsid assembly protein [B. Roizman and A. Sears, *Herpes Simplex Viruses and Their Replication*, in *Human Herpesviruses*, 11-68, (B. Roizman, R. J. Whitley, and C. Lopez, eds. 1993)]. Gao et al constructed and characterized a null mutant virus ("m100") that contains a deletion within the protease domain of the HSV-1 UL26 gene [J. Virol. 68:3702-3712 (1994)]. The mutant virus could be propagated on a complementing cell line but not on noncomplementing Vero cells, indicating that the protease domain of UL26 is essential for viral replication in cell culture. DNA replication occurred at near wild-type levels, but the viral DNA was not processed to unit genome length or encapsidated.

We have generated a recombinant virus to further investigate the role of this domain with respect *in vivo* effects. The recombinant virus is avirulent *in vivo* and induces immunity to challenge by wild-type HSV-1.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the construction of four plasmids. (A) Plasmid pMON15839a contains a 3.4 kb *KpnI* fragment of HSV-1 ("KOS") upstream of the SV40 polyadenylation signal. (B) Plasmid pMON15840 has a UL26 ORF downstream of the herpesvirus ICP6 promoter region. Translation of UL26 begins at methionine 10. (C) Sequence of the multiple cloning site inserted into the *BspEI/BclI*-digested pMON27005. (D) Plasmid pMON15835 contains an ICP6- β -glucuronidase cassette inserted into the *BclI* site of pMON27005. The UL26 ORF is shown as the stippled box, the ICP6 promoter region is shown as the hatched box. The plasmids are not drawn to scale. Abbreviations: "K", *KpnI*; "B", *BspEI*; "S", *SmaI*.

Figure 2 shows the Southern blot analysis of recombinant viruses. Viral DNA was digested with *NotI* or *KpnI*, transferred to nitrocellulose and hybridized to an α -³²P-dGTP-labeled 3.4 kb *KpnI* fragment shown in Figure 1A. Schematics show the restriction maps of the viruses. The hatched region in the UL26 deletion schematic is the ICP6- β -glucuronidase insertion in the protease domain. Lane 1, HSV-1 ("17"); Lane 2, HSV/UL26/ β -gluc; Lane 3, HSV/UL26/res. Abbreviations: "N", *NotI*; "K", *KpnI*.

Figure 3 is a graphical representation which shows the multistep growth curves of mutant viruses. BHK/UL26 helper or BHK/C2 cells were infected at an MOI of 0.1. Cells were harvested at various time points and the virus was titered on BHK/UL26 helper cells. Circles represent virus from BHK/UL26 helper cells and squares represent virus from BHK/C2 cells. The error bars represent the ranges of duplicate determinations.

Figure 4 shows the capsid assembly protein processing results. BHK/C2 and BHK/UL26 helper cells were infected with an MOI of 5 for 18 hours. Cells were harvested and

proteins were separated on a 14% denaturing SDS-polyacrylamide gel, transferred to Immobilon membrane, and probed with antisera generated against a peptide of the HSV-1 capsid assembly protein (HSVAs-414). The open star indicates the major unprocessed assembly protein and the closed star indicates the processed form. Lane 1, mock infected cells; Lane 2, wild-type HSV-1; Lane 3, HSV/UL26/ β -gluc; Lane 4, HSV/UL26/res.

Figure 5 is a graphical representation which shows the viral challenge of mice. Mice were inoculated intraperitoneal (i.p.) with 6×10^5 pfu of each virus and scored for mortality. The survivors and control mice (age- and sex-matched) were challenged with another dose of wild-type virus on day 32.

Figure 6 is a graphical representation which shows i.p. or subcutaneous (s.q.) inoculation of mice inoculated with media or 10^2 , 10^4 , or 10^6 pfu of HSV/UL26/ β -gluc. Mice were inoculated on day 1 either i.p. (A) or s.q. (B). On day 31 the mice were challenged with 10^7 pfu of wild-type HSV-1 given i.p.

DESCRIPTION OF THE INVENTION

The present invention describes a vaccine comprising an assembly-deficient herpesvirus. Preferably, the herpesvirus contains an inactivated form of an essential protease gene. More preferably, the protease is required for the processing and assembly of immature, noninfectious capsid particles into mature, infectious capsid particles.

The protease gene can be inactivated by a method selected from deletion, insertion, substitution and any combination of deletion, insertion, or substitution. Preferably, the protease gene is inactivated by deletion of viral DNA and insertion or substitution of nonviral (heterologous) DNA. More preferably, the essential

protease gene is inactivated by deletion of viral DNA and insertion of nonviral (heterologous) DNA.

Preferably, the inactivated protease gene is selected from HSV-1 UL26, HSV-2 UL26, and HCMV UL80. More preferably, the protease is encoded by HSV-1 UL26.

The invention includes herpesviruses selected from HSV-1, HSV-2, HCMV, SCMV, VZV, EBV, HHV-6, HHV-7, HHV-8, PRV, BHV and EHV. Preferably, the virus is HSV-1 or HSV-2. More preferably, the virus is HSV-1. Preferably, the vaccine comprises the assembly-deficient mutant virus designated HSV/UL26/ β -gluc.

Preferably, the vaccine comprises a dose between about 10 and about 10^6 plaque-forming units of said assembly-deficient herpesvirus.

Additionally, the present invention describes a method of manufacturing a vaccine comprising an assembly-deficient herpesvirus, by preparing stocks of the virus in a recombinant cell line capable of generating properly assembled virus. Preferably, the method of manufacturing a vaccine uses a virus selected from HSV-1, HSV-2, HCMV, SCMV, VZV, EBV, HHV-6, HHV-7, HHV-8, PRV, BHV, and EHV. More preferably, the method of manufacturing a vaccine uses virus selected from HSV-1 and HSV-2. Even more preferably, the method of manufacturing a vaccine uses a virus derived from HSV-1.

The present invention also describes a use of an assembly-deficient herpesvirus in a preparation of a vaccine.

Additionally, the present invention describes a method of immunizing a susceptible mammal against a herpesvirus by administering a vaccine comprising an assembly-deficient herpesvirus. Preferably, the susceptible mammal is selected from human, monkey, cow, horse, sheep, and pig. More preferably, the mammal is human.

The present invention also describes a mutant

herpesvirus containing an inactivated form of an essential protease gene required for the processing and assembly of immature, noninfectious capsid particles into mature, infectious capsid particles, said essential protease gene
5 is inactivated by deletion of viral DNA and insertion of nonviral (heterologous) DNA.

Preferably, the essential protease gene is inactivated by deletion of a portion of the essential protease gene and insertion of a nonviral (heterologous) DNA segment
10 comprising a reporter gene under the control of an inducible promoter. More preferably, the essential protease gene is the HSV-1 UL26 gene. More preferably, the inducible promoter is the HSV-1 ICP6 (UL39) promoter. Even more preferably, the nonviral (heterologous) DNA segment
15 comprises the gusA gene encoding E. coli beta-glucuronidase under the control of an HSV-1 ICP6 (UL39) promoter.

The present invention additionally describes a recombinant host cell line expressing an essential protease gene under the control of an inducible promoter.
20 Preferably, the recombinant host cell line is derived from a mammalian source. More preferably, the recombinant host cell line is derived from a rodent source. Even more preferably, the recombinant host cell line is BHK-21. Preferably, the inducible promoter is a herpesvirus
25 promoter. More preferably, the inducible promoter is the HSV-1 ICP6 (UL39) promoter.

The present invention also describes a method of making mutant herpesviruses by introducing the virus into a recombinant host cell line and recovering mature viral
30 particles harboring the mutant viral genome.

Definitions

The phrase "assembly-deficient" is intended to mean that the virus is able to replicate its DNA, but is unable
35 to complete the steps of cleaving that DNA into genome-

length pieces and packaging that DNA into viral capsids.

The phrase "mature virion" is intended to mean a viral particle capable of infection in a susceptible host or cell type. The phrase "nonviral (heterologous) DNA" is intended to mean DNA that is not derived from a herpesvirus genome. The phrase "nonessential gene" is intended to mean a gene that can be disrupted by deletion, insertion, substitution, or a combination of deletion, substitution, and insertion of other DNA, and that a recombinant virus containing this disrupted gene can propagate in cultured cells that do not express nondisrupted copies of the same gene. The phrase "essential gene" is intended to mean a gene that is not a nonessential gene. The phrase "essential viral protease gene" is intended to mean an essential viral gene that encodes a protease.

EXPERIMENTAL

Baby hamster kidney cells (BHK-21) were obtained from American Type Culture Collection (ATCC) (Rockville, MD) and were cultured in Dulbecco's modified Eagle's media supplemented with 10% fetal bovine sera (JRH Biosciences, Lenexa, KS), 2 mM additional L-glutamine (JRH Biosciences) and 100 µg-units/ml of penicillin-streptomycin (JRH Biosciences). HSV-2 strain MS was obtained from ATCC and HSV-1 strain 17 was obtained from Dr. R. Lausch, University of South Alabama. Viral DNA was isolated and purified according to D'Aquila and Summers [J. Virol. 61:1291-1295 (1987)] for stock quantities and according to DeLuca et al [J. Virol. 52:767-776 (1984)] and Rader et al [J. Gen. Virol. 74:1858-1869 (1993)] for rapid Southern blot evaluation.

To generate cell lines that complement the defect in the UL26 gene, BHK-21 cells were cotransfected with 10 µg plasmid DNA containing the complementing sequences (see below) and 1 µg

SV2neo [P. J. Southern and P. Berg. J. Mol. Appl. Genet. 1:327-341 (1982)] using LipofectAmine Reagent (GIBCO/BRL/Life Technologies, Inc., Grand Island, NY) according to the manufacturer's instructions. After two days, cells were treated
5 with trypsin and diluted into media containing 400 µg/ml G418 (Geneticin, Gibco/BRL/Life Technologies, Inc.). Individual colonies were isolated and expanded for determination of helper function.

Two plasmids were made for engineering a cell line
10 that would complement a protease defective HSV-1. First, a 3.4 kb *KpnI* fragment from HSV-1 (KOS) (from P. Olivo, Washington University) containing the entire UL26 promoter region and open reading frame (ORF) was subcloned into the *KpnI* site of pMON3327 [Highkin et al, Poultry Science
15 70:970-981 (1991)] such that the SV40 polyadenylation signal is 3' to the UL26 ORF. This plasmid was designated pMON15831a (Figure 1). The second plasmid consists of the UL26 ORF under control of the HSV-1 ICP6 (UL39) promoter region. This plasmid was synthesized in several steps.
20 First, the 320 bp *SmaI* fragment containing the 5' end of the UL26 ORF starting at nucleotide 18 was subcloned into the *SmaI* site of pUC18 resulting in pMON15838. The 1642 bp *BsgI*-*KpnI* fragment from pMON27010 was inserted into *BsgI*-*KpnI* digested pMON15838 to yield pMON15839. pMON27010 has
25 the 3.4 kb *KpnI* fragment from HSV-1 (strain 17) in pUC18. The 1956 bp *EcoRI*-*HindIII* fragment was isolated from pMON15839 and the ends were filled-in using Klenow polymerase before ligating to pMON15834 which had been digested with *BamHI* and filled in as above. The resulting
30 plasmid was designated pMON15840 (Figure 1). Plasmid pMON15834 has the filled-in 633 bp *XhoI*-*SnaBI* fragment of HSV-1 (strain 17) that directs the expression of the ICP6 ORF in the *SmaI* site of pMON3327.

A β -glucuronidase cassette was inserted into the UL26
35 ORF as follows: The β -glucuronidase cassette under control

of the HSV-1 ICP6 promoter region was constructed by isolating a 633 bp *Xho*I-*Sna*BI fragment from pMON27002. pMON27002 has the 16,191 bp *Sse*8387I D fragment from HSV-1 (strain 17) in pNEB193 (New England Biolabs, Beverly, MA).
5 The *Xho*I site was filled-in using Klenow polymerase and was ligated into the filled-in *Nco*I site in pMON14327 (Luckow et al, J. Virol. 67:4566-4579 (1993)) which contains the β -glucuronidase gene. The new plasmid is designated pMON15833 (Figure 1). The *Not*I H fragment (6542 bp)
10 containing the HSV-1 (strain 17) UL26 ORF was subcloned into *Not*I-digested pBS2SKP (Stratagene, La Jolla, CA) to generate plasmid pMON27005. pMON27005 was digested with *Bsp*EI and *Bcl*I. A polylinker containing multiple cloning sites and complementary ends was inserted to create plasmid
15 pMON27026 (Figure 1). To construct a cassette for recombination with wild-type HSV-1 (strain 17), the 2871 bp ICP6- β -glucuronidase sequences were removed from pMON15833 by *Bam*HI digestion and ligated into *Bcl*I-digested pMON27026. The new vector is designated pMON15835 (Figure
20 1).

BHK cells were seeded at 4×10^5 cells per 60 mm dish one day prior to transfection. One microgram of genomic viral DNA and an equimolar amount of linearized plasmid containing the desired sequence changes were mixed with 25
25 μ g of LipofectAmine in OptiMem media (Gibco/BRL/Life Technologies) and added to the cells for 4 hours. The media was aspirated and replaced by growth media. The transfected cells were completely lysed before the harvesting of the supernatant. Clarified, serially-diluted
30 supernatant (0.8 ml) was plated onto the helper cell line in 60 mm dishes at 37 °C for 60 minutes. The inoculum was removed and the cells were overlaid with a 1% agarose (JRH Biosciences)/10% FBS/EMEM (BioWhitaker, Walkersville, MD). After the formation of visible cytopathic effects, 4 ml
35 Dulbecco's phosphate-buffered saline (JRH Biosciences)

containing 300 µg/ml X-gluc (BioSynth AG, Switzerland) and 80 µg/ml neutral red (Sigma, St. Louis, MO) were added, and plaques were picked using a Pasteur pipette. For viruses containing the β-glucuronidase gene, blue plaques were selected. For rescued viruses (see below), clear plaques were selected. The viruses were plaque-purified three times or purified by limiting dilution. Purified virus was isolated and the DNA was analyzed by restriction enzyme analysis and Southern blotting [Maniatis et al, Molecular Cloning, A Laboratory Manual (1982)].

Analysis of the clear plaque virus in the blue plaque virus stock was done by the polymerase chain reaction (PCR) (Saiki et al, Science. 239:487-491 (1988)). Two oligonucleotides that flanked the unique *BsgI* site in the HSV-1 (strain 17) UL26 ORF were synthesized (Genosys, The Woodlands, TX). The forward primer was identical to nucleotides 50,913 to 50,932 of the HSV genome [5'-GGGCGAGTTGGCATTGGATC-3', McGeoch et al, J. Gen. Virol. 69:1531-1574 (1988)]. The reverse primer was complementary to sequences 51,195 to 51,175 of the HSV-1 genome (5'-AGACCGAGGGCAGGTAGTT-3'). Virus was extracted with phenol:chloroform and the viral DNA was ethanol-precipitated. The PCR was carried out using the GeneAmp PCR kit (Perkin-Elmer-Cetus, Norwalk, CT). The reaction products were analyzed on 5% polyacrylamide gels.

Peptide antibodies were raised in rabbits against regions corresponding to amino acids 414 through 428. Peptide HSVAs-414 (C-PAAGDPGVRGSGKR) was synthesized by Chiron Mimotopes Pty. Ltd. (Raleigh, NC) and purified to greater than 95% purity. HSVAs-414 mapped to the central region of the capsid assembly region of the UL26 and UL26.5 genes. The peptide had a free acid at the C-terminus and was conjugated to diphtheria toxoid at the N-terminus. Rabbits were inoculated with 100 µl of 1 µg/ml of protein mixed with an equal volume of Freund's complete adjuvant,

boosted with the same material in Freund's incomplete adjuvant at 4 week intervals beginning at week 2, and bled 10 and 17 days after boosting.

Cells were seeded in wells of six-well dishes at 5 x 10⁵ cells/well. The next day, cells were infected with a multiplicity of infection (MOI) of 5 pfu/cell for 60 minutes at 37 °C with occasional gentle rocking. The inoculum was aspirated and growth media was added. At 18 hours post infection, the media was aspirated and 400 µl of 1X Protein Disruption Buffer (Novex, San Diego, CA) containing 10% β-mercaptoethanol were added. Proteins were separated on 14% Tris-glycine SDS-polyacrylamide gels (Novex) for 1.5 hours at 125 volts. The gels were incubated for 10 minutes in 1X Transfer Buffer (Novex) and blotted to Immobilon-P membranes (Novex) for 1-2 hours at 30 volts. The membranes were incubated in 1X Tris-buffered saline containing Tween 80 (TTBS), supplemented with 5% powdered milk for at least one hour (typically overnight). The blot was rinsed twice with TTBS for 15 minutes, and incubated with primary antibody for 1 hour at a dilution of 1/1000. The blot was rinsed twice with TTBS for 15 minutes before incubating with secondary antibody (alkaline phosphatase conjugated goat anti-rabbit antibody, Promega, Madison, WI) for 1 hour at a dilution of 1/4000. The alkaline phosphatase was visualized by incubating the blot in nitro blue tetrazolium (NBT)/5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Promega) for 5 to 15 minutes, and the reaction stopped by rinsing extensively in H₂O.

Viral replication was examined by multistep growth analysis on the BHK/UL26 helper line and on BHK cells that did not contain the helper function but were G418-resistant (BHK/C2). Cells (1 x 10⁵) were seeded in wells of a 24-well plate and infected with an MOI of 0.1 plaque-forming-units (pfu) per cell. At various times post infection, the infected cells were subjected to three rounds of freeze-

thawing [Tengelsen et al, J. Virol. 67:3470-3480 (1993)] and the lysates were titered on the BHK/UL26 helper line.

To generate cell lines capable of supporting replication recombinant viruses with a deletion and insertion within the UL26 open reading frame, BHK cells were cotransfected with pMON15831a which has the 3.4 kb *KpnI* fragment of HSV-1 (KOS) 5' to the SV40 polyadenylation signal (Figure 1) and SV2neo. G418-resistant cells were isolated and shown by Southern blot analysis to contain the HSV-1 *KpnI* fragment. To determine which cell line would express the UL26 gene products, the cell lines were infected with HSV-2 (MS) to stimulate the UL26 promoter in the cell. HSV-1-specific anti-peptide antisera, generated by inoculating rabbits with the peptide HSVAs-414 conjugated to diphtheria toxin, was used to identify expression of the cellular UL26 gene products (data not shown). This cell line, designated BHK/UL26/8, was used for generation of recombinant viruses. A G418-resistant cell line which was cotransfected with pMON3327 and SV2neo serves as a control and is designated BHK/C2. An additional helper cell line (BHK/UL26 helper) was isolated after the discovery that significant amounts of rescued virus were being generated due to recombination with the *KpnI* fragment present in BHK/UL26/8. This second line was transfected with plasmid pMON15840 which has the UL26 ORF behind the ICP6 promoter and lacks the large amount of HSV DNA 5' to the UL26 ORF contained in pMON15831a. Translation from this integrated plasmid began at the methionine at the natural amino acid 10. Candidate cell lines were screened for their ability to support growth of the blue plaque phenotype recombinant virus (see below). A cell line isolated from this latter screening that supports the growth of the UL26 mutant virus was designated the BHK/UL26 helper cell line.

Cell line BHK/UL26/8 was transfected with HSV-1

(strain 17) genomic DNA and plasmid pMON15835 which contains a *NotI* fragment of HSV-1 (strain 17) with a deletion in the protease domain of the UL26 ORF and an insertion of the bacterial β -glucuronidase gene under control of the HSV-1 (strain 17) ICP6 promoter (Figure 1). After cell lysis, the supernatant was serially-diluted on BHK/UL26/8 and blue plaques were identified after 4 to 5 days post infection. The blue plaques were picked and plaque-purified three times. The recombinant virus was designated HSV/UL26/ β -gluc. Plaque purification indicated poor segregation between the blue phenotype recombinant virus and a clear plaque phenotype virus which appeared to have a growth advantage, even on the helper cell line.

To determine the genotype and source of the clear plaque virus, DNA amplification was performed on cell-free viral DNA from the mixed culture of blue and clear plaque phenotype viruses. Amplification of a 283 bp fragment indicated the presence of wild-type virus in the stock. The PCR product was digested with *BsgI*, which cuts the fragment from wild-type (strain 17) DNA, but does not cut the fragment from wild-type (strain KOS) DNA, which is the source of DNA in the helper cell (data not shown). Lack of digestion of the PCR product by *BsgI* indicated that the wild-type virus was actually a revertant generated by recombination between the blue plaque phenotype virus and the UL26 sequences in the helper cell line. The rescued virus was designated HSV/UL26/res.

In order to generate a more pure stock of HSV/UL26/ β -gluc, a new helper cell line (BHK/UL26 helper) was isolated in which the amount of HSV DNA sequence 5' to the UL26 ORF was eliminated and replaced with the ICP6 promoter region fragment (pMON15840, Figure 1). Propagation of HSV/UL26/ β -gluc on this cell line resulted in only the blue plaque phenotype.

Viral DNA from wild-type (strain 17), HSV/UL26/ β -gluc

and the rescued virus was digested with *NotI* or *KpnI*. The digested DNA was analyzed by Southern blot analysis after probing with a restriction fragment containing the full length UL26 open reading frame and 5' flanking sequences.

5 The results showed the expected pattern of digestion (Figure 2). Wild-type and rescued virus showed the same pattern as expected with both *NotI* (6.3 kb) and *KpnI* (3.4 kb) digestion (Lanes 1 and 3). Deletion of a small region of the UL26 ORF and insertion of the β -glucuronidase gene

10 resulted in addition of a new *NotI* site (resulting in predicted 4.8 and 4.4 kb fragments) and a new *KpnI* site (resulting in a 4.0 and 2.1 kb fragments) (Lane 2) in HSV/UL26/ β -gluc.

Growth curves were determined for the viruses on the

15 different cell lines. At various times post infection, the cells were harvested and freeze-thawed three times before plating on BHK/UL26 helper cells. The results indicated that HSV/UL26/ β -gluc failed to replicate in BHK/C2 cells but grew with wild-type kinetics on the BHK/UL26 helper

20 cell line. The wild-type (strain 17) HSV-1 and the rescued virus replicated to identical titers and at identical rates on both BHK/C2 and the BHK/UL26 helper cell lines (Figure 3).

Since it has been shown by transient transfection

25 experiments in mammalian cells, bacteria and ts1201 that certain mutations in the 5' region of UL26 fail to cleave the capsid assembly protein [reviewed in Gao et al, J. Virol. 68:3702-3712 (1994)], HSV/UL26/ β -gluc was used to infect BHK/C2, BHK and BHK/UL26 helper cells at an MOI of

30 5. At 18 hours post infection, the cells were lysed in SDS-PAGE sample buffer and proteins separated on a 14% SDS-PAGE gel. After transfer to Immobilon P membranes, the blots were incubated in antisera against the HSV-1 capsid assembly protein. The results are shown in Figure 4.

35 Infection of BHK/C2 cells by HSV/UL26/ β -gluc resulted in a

failure to process the capsid assembly protein to a lower molecular weight form. Infection of BHK/helper cells by HSV/UL26/ β -gluc showed that the capsid assembly protein was appropriately processed. The rescued recombinant virus
5 (HSV/UL26/res) processed the capsid assembly protein in both cell lines as did wild-type HSV-1 (lanes 2 and 4). The capsid assembly protein was made at normal levels during infection in both helper and non-helper cells but is not cleaved in the non-helper cells. The HSV/UL26/ β -gluc
10 recombinant fails to process the capsid assembly protein and has restricted growth.

Female Swiss-Webster mice (12-14 grams, Charles Rivers Laboratories, Wilmington, MA) were inoculated with virus intraperitoneally or subcutaneously with 100 μ l volumes.
15 Subcutaneous inoculations were delivered on the dorsal side near the base of the tail after brief CO₂/O₂ treatment of the mice. Virus was resuspended in DMEM containing 5% FBS unless otherwise noted. Food and water were given *ad libitum*. Mice were euthanized if they became moribund due
20 to paralysis.

Mice were inoculated i.p. with 6×10^5 pfu (as determined on the helper cell line) of either the wild-type (strain 17) HSV, HSV/UL26/ β -gluc, or the rescued virus in a 100 μ l volume. As shown in Figure 5, mice infected with
25 wild-type (strain 17) or the rescued virus died by day 7 post infection. All mice infected with HSV/UL26/ β -gluc survived. The animals that originally received HSV/UL26/ β -gluc were challenged with wild-type HSV-1 (strain 17), i.p., at the same dose given initially. Age- and sex-
30 matched naive mice were also inoculated. One of the HSV/UL26/ β -gluc infected mice was found dead about 16 hours post infection with the wild-type virus. Death was probably not related to the virus since it occurred so quickly after infection. The other 9 mice survived the
35 wild-type virus challenge. The naive mice were susceptible

to wild-type virus infection although it took longer for the virus to cause morbidity and mortality (Figure 5).

In a second experiment, mice were inoculated i.p. with ten-fold serial dilutions of HSV/UL26/ β -gluc starting at the same inoculum used in the initial experiment. On day 39, the mice were challenged i.p. with 6×10^6 pfu of HSV-1 (strain 17). This dose of wild-type virus was 10-fold higher than that in the initial experiment and resulted in 90% death in the mice that were initially inoculated with DMEM/5% FBS (Table 1, mock-infected set). Again, within 16 hours, 6 mice were found dead. Two of these were in the set that were previously inoculated with 10 pfu of HSV/UL26/ β -gluc and 4 were in the set that were previously given 1×10^5 pfu of HSV/UL26/ β -gluc. There was a significant difference among the six survival curves ($p < 0.02$, log rank test). The data suggests that mice that were inoculated with HSV/UL26/ β -gluc survived in a dose-dependent manner (Table 1). The survival curves of the mice receiving the highest dose of HSV/UL26/ β -gluc were statistically different from the mock group ($p = 0.023$, log rank test).

Table 1.

HSV/UL26/ β - gluc	% Survival*
mock	10
6×10^1 pfu	12.5
6×10^2 pfu	30
6×10^3 pfu	60
6×10^4 pfu	50
6×10^5 pfu	83.3

* Survival determined on day 20 after i.p. challenge with 6×10^6 pfu of wild-type HSV-1 (strain 17). $N = 10$ for all groups except for the 6×10^1 ($N = 8$) and 6×10^5 ($N = 6$) due to the early death.

In a third experiment, virus stocks were prepared as previously but were resuspended in DMEM without any FBS. Sets of ten mice were inoculated with DMEM alone or with increasing doses of HSV/UL26/ β -gluc by either i.p. or s.q. routes. After one month, all mice were challenged with 10^7 pfu of wild-type virus by i.p. inoculation. Some controls for rapid death included animals that received i.p. media then challenged with i.p. media, HSV/UL26/ β -gluc and then media or, HSV/UL26/ β -gluc and then challenged with HSV/UL26/ β -gluc. None of these animals died during the course of the experiment. None of the experimental animals died within 24 hours of challenge. Of these, 90 animals had received two inoculations of virus and one would expect about 10-12% to have died rapidly. The results with the experimental groups are shown in Figure 6A and 6B. There was a significant difference among the survival curves for both the i.p. ($p < 0.01$) and s.q. ($p < 0.01$) inoculations (log rank test). Regression analysis shows that there is a dose-dependent effect of HSV/UL26/ β -gluc on survival ($p < 0.05$, Cochran-Armitage test) for both groups.

It is expected that this virus would have reduced efficiency and reactivate poorly, if at all. The fact that the mutation effects a late gene function suggests that the recombinant virus may be more efficacious in inducing immunity than viruses that have deletions in immediate early or early genes. The assembly-defective HSV/UL26/ β -gluc virus is a member of a new class of vaccine candidates with a defect in late gene activity.

It is anticipated that the defect in the essential gene described in an assembly-deficient virus can be incorporated in a virus with other mutations in essential or nonessential genes. Such genes, like ICP47 of HSV-1, may modulate the host's ability to mount an immune reaction to the virus [Hill et al, Nature 375:411-415 (1995); Fröh

et al, Nature 375:415-417 (1995)].

The vaccines of the present invention can be of a lyophilized form or suspended in a pharmaceutically-acceptable carrier. Suitable suspensions can include
5 phosphate buffer, saline, glucose, inactivated serum, excipients, and adjuvants. The vaccine can be prepared and used according to standard techniques well known in the art [reviewed in R. L. Burke, Seminars in Virology, 4:187-197, (1993)]. The effective dose may also be determined by
10 standard techniques well known in the art. Generally, vaccines are formulated in a suitable sterilized buffer and administered by intradermal, intramuscular, or subcutaneous injection at a dosage of between 10^3 and 10^9 pfu/kg. The vaccine can also be formulated for oral or ocular
15 administration in vehicles known in the art.

The foregoing detailed description is given to facilitate clearness of understanding only, and no unnecessary limitations are to be understood therefrom, as modifications within the scope of the invention will be
20 obvious to those skilled in the art.

What is claimed:

1. A vaccine comprising an assembly-deficient herpesvirus.
2. The vaccine of Claim 1 wherein said
5 herpesvirus contains an inactivated form of an essential protease gene.
3. The vaccine of Claim 2 wherein said essential protease gene is required for the processing and
assembly of immature, noninfectious capsid particles
10 into mature, infectious capsid particles.
4. The vaccine of Claim 1 wherein said herpesvirus is selected from HSV-1, HSV-2, HCMV, SCMV, VZV, EBV, HHV-6, HHV-7, HHV-8, PRV, BHV and EHV.
5. The vaccine of Claim 4 wherein said
15 herpesvirus is HSV-1 or HSV-2.
6. The vaccine of Claim 4 wherein said herpesvirus is HSV-1.
7. The vaccine of Claim 3 wherein said essential protease gene is selected from HSV-1 UL26, HSV-2 UL26,
20 and HCMV UL80.
8. The vaccine of Claim 7 wherein said essential protease gene is HSV-1 UL26.
9. The vaccine of Claim 2 wherein said essential protease gene is inactivated by a method selected from
25 deletion, insertion, substitution of DNA, and any combination of deletion, insertion, or substitution of DNA.
10. The vaccine of Claim 9 wherein said essential protease gene is inactivated by deletion of viral DNA
30 and insertion of nonviral (heterologous) DNA.

11. The vaccine of Claim 1 comprising between about 10^5 and about 10^6 plaque-forming units of said herpesvirus.

12. The vaccine of Claim 1 wherein said assembly-deficient herpesvirus comprises the strain designated HSV/UL26/ β -gluc.

13. A method of manufacturing a vaccine of Claim 1 comprising an assembly-deficient herpesvirus, by preparing stocks of said herpesvirus in a recombinant cell line capable of generating properly-assembled virus, and suspending said virus in a pharmaceutically-acceptable carrier.

14. The method of manufacturing a vaccine of Claim 13 wherein said essential protease gene is an HSV-1 UL26 gene.

15. The method of Claim 13 wherein said vaccine comprises the strain HSV/UL26/ β -gluc.

16. The method of Claim 13 wherein said cell line is mammalian.

17. The method of Claim 16 wherein said cell line supports replication of said herpesvirus.

18. The method of Claim 17 wherein said cell line is the cell line designated BHK/UL26/8.

19. The method of Claim 17 wherein said cell line comprises the cell line designated BHK/UL26 helper.

20. A use of an assembly-deficient herpesvirus in a preparation of a vaccine.

21. A method of immunizing a mammal against a herpesvirus by administering a vaccine of Claim 1 in a pharmaceutically-acceptable carrier.

22. The method of Claim 21 where the mammal is selected from human, monkey, cow, horse, sheep and pig.

23. The method of Claim 22 where the mammal is human.

5 24. A mutant herpesvirus containing an inactivated form of an essential protease gene required for the processing and assembly of immature, noninfectious capsid particles into mature, infectious capsid particles, with said essential protease gene
10 inactivated by deletion of viral DNA and insertion of nonviral (heterologous) DNA.

25. A mutant virus according to Claim 24 wherein said virus is selected from HSV-1, HSV-2, HCMV, SCMV, VZV, EBV, HHV-6, HHV-7, HHV-8, PRV, BHV and EHV.

15 26. A mutant virus of Claim 25 wherein said essential protease gene is HSV-1 UL26.

27. A mutant virus of Claim 24 wherein a portion of said essential protease gene is deleted and replaced by a nonviral (heterologous) DNA segment comprising a
20 reporter gene under the control of an inducible herpesvirus HSV-1 promoter.

28. A mutant virus of Claim 27 wherein said reporter gene is selected from gusA encoding beta-glucuronidase, lacZ encoding beta-galactosidase, phoA
25 encoding alkaline phosphatase, gfp encoding green fluorescent protein, and aeq encoding aequorin.

29. A mutant virus of Claim 28 wherein said reporter gene is the gusA gene encoding E. coli beta-glucuronidase.

30 30. A mutant virus of Claim 27 wherein said inducible herpesvirus promoter is the HSV-1 ICP6 (UL39) promoter.

31. A recombinant host cell line expressing an essential herpesvirus protease gene under the control of an inducible non-protease promoter.

32. A recombinant host cell line of Claim 31,
5 wherein said host cell line is from a rodent source.

33. A recombinant host cell line of Claim 32,
wherein said host cell line is BHK-21.

34. A recombinant host cell line of Claim 31
wherein said inducible non-protease promoter is the
10 HSV-1 ICP6 (UL39) promoter.

35. A method of making mutant herpesviruses of Claim 24 by introducing said virus into a recombinant host cell line and recovering mature viral particles harboring the mutant viral genome.

15




Fig. 1




Fig. 2




Fig. 3





Fig. 4

Fig. 5






Fig. 6A





Fig. 6B



PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/245, C12N 15/52		A3	(11) International Publication Number: WO 98/04286
			(43) International Publication Date: 5 February 1998 (05.02.98)
(21) International Application Number: PCT/US97/14192		(74) Agents: BENNETT, Dennis, A. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).	
(22) International Filing Date: 25 July 1997 (25.07.97)			
(30) Priority Data: 08/687,820 26 July 1996 (26.07.96) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US 08/687,820 (CON) Filed on 26 July 1996 (26.07.96)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).		(88) Date of publication of the international search report: 14 May 1998 (14.05.98)	
(72) Inventors; and (75) Inventors/Applicants (for US only): HIPPENMEYER, Paul, J. [US/US]; 126 Chippenham, St. Louis, MO 63005 (US). RANKIN, Anne, M. [US/US]; 718 Inglestone, Ballwin, MO 63021 (US). LUCKOW, Verne, A. [US/US]; 233 Portico Drive, Chester, MO 63017 (US).			

(54) Title: ASSEMBLY-DEFICIENT HERPESVIRUS VACCINE



(57) Abstract

A vaccine is described which comprises an assembly-deficient herpesvirus. The mutant herpesvirus is capable of infecting and undergoing DNA replication in the cells of a susceptible mammal, but is defective in capsid assembly and formation of mature virion particles. The assembly-deficient herpesvirus is avirulent and capable of generating a protective immune response in a vaccinated mammal.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/14192

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K39/245 C12N15/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 96 38551 A (MERCK & CO. INC.) 5 December 1996 see page 1, line 18 - page 2, line 2 see page 6, line 1 - line 6 see page 8, line 18 - line 22 see page 8, line 29 - page 9, line 10 see page 23, line 18 - line 23 ---	24-26, 31,35
X	WO 92 13943 A (SMITHKLINE BEECHAM BIOLOGICALS S.A.) 20 August 1992 see page 5, line 34 - page 6, line 7; claim 11; example 6 ---	1-14,16, 17,20-23 15,18, 19,24-35
Y	---	

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (see specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

5 March 1998

Date of mailing of the international search report

27.03.98

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Olsen, L

INTERNATIONAL SEARCH REPORT

nal Application No

PCT/US 97/14192

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	M.F. AL-KOBAISI ET AL.: "The Herpes simplex virus UL33 gene product is required for the assembly of full capsids" VIROLOGY, vol. 180, 1991, pages 380-388, XP002057787 see the whole document ---	1-35
Y	D.R. THOMSEN ET AL.: "Assembly of the Herpes simplex virus capsid: requirement for the carboxyl-terminal twenty-five amino acids of the proteins encoded by the UL26 and UL26.5 genes" JOURNAL OF VIROLOGY, vol. 69, 1995, pages 3690-3703, XP002057788 see the whole document ---	1-35
X	WO 96 12007 A (MERCK & CO. INC.) 25 April 1996 see claim 4; example 1 -----	31

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 97/14192

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9638551 A	05-12-96	NONE	
WO 9213943 A	20-08-92	AU 657731 B	23-03-95
		AU 1182992 A	07-09-92
		CA 2101639 A	01-08-92
		EP 0571410 A	01-12-93
		JP 6507066 T	11-08-94
		NZ 241476 A	23-12-93
		NZ 245842 A	23-12-93
WO 9612007 A	25-04-96	AU 3952895 A	06-05-96



**CORRECTED
VERSION***

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/245, C12N 15/52		A3	(11) International Publication Number: WO 98/04286
			(43) International Publication Date: 5 February 1998 (05.02.98)
(21) International Application Number: PCT/US97/14192		(74) Agents: BENNETT, Dennis, A. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).	
(22) International Filing Date: 25 July 1997 (25.07.97)			
(30) Priority Data: 08/687,820 26 July 1996 (26.07.96) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant (63) Related by Continuation US 08/687,820 (CON) Filed on 26 July 1996 (26.07.96)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).		(88) Date of publication of the international search report: 14 May 1998 (14.05.98)	
(72) Inventors; and (75) Inventors/Applicants (for US only): HIPPENMEYER, Paul, J. [US/US]; 126 Chippenham, St. Louis, MO 63005 (US). RANKIN, Anne, M. [US/US]; 718 Inglestone, Ballwin, MO 63021 (US). LUCKOW, Verne, A. [US/US]; 233 Portico Drive, Chester, MO 63017 (US).			

(54) Title: ASSEMBLY-DEFICIENT HERPESVIRUS VACCINE



(57) Abstract

A vaccine is described which comprises an assembly-deficient herpesvirus. The mutant herpesvirus is capable of infecting and undergoing DNA replication in the cells of a susceptible mammal, but is defective in capsid assembly and formation of mature virion particles. The assembly-deficient herpesvirus is avirulent and capable of generating a protective immune response in a vaccinated mammal.

* (Referred to in PCT Gazette No. 29/1998, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ASSEMBLY-DEFICIENT HERPESVIRUS VACCINE

FIELD OF THE INVENTION

5 This invention is in the field of viral vaccines, and
specifically relates to the generation of assembly-
deficient mutant herpesviruses, vaccines comprising
assembly-deficient mutant herpesviruses, and methods for
the production and manufacture of assembly-deficient
10 herpesvirus vaccines.

BACKGROUND OF THE INVENTION

There is a great need for therapies for the treatment
15 of viral diseases. While antiviral drugs such as
zidovudine, used in the treatment of human immunodeficiency
virus (HIV), and drugs such as ganciclovir, acyclovir, and
foscarnet are used in the treatment of herpesvirus
infections, significant side effects often limit their
20 effectiveness. The selection and spread of drug-resistant
viruses also limits the effectiveness of small molecular
weight antiviral drugs. This is a particularly significant
problem for drugs targeted against RNA viruses such as HIV,
which have a relatively high mutation rate compared to most
25 DNA viruses.

Antiviral vaccines are a viable alternative to
postinfection antiviral drug treatments. Ideally,
antiviral vaccines protect against primary disease and
recurring infections. Efficacy against a particular
30 disease is crucial to the development of a vaccine
strategy. Regulatory concerns, particularly related to the
safety of vaccines intended for prophylactic use in healthy
individuals, must also be considered.

While herpesvirus vaccines have been an active area of
35 both academic and commercial interest, induction of a good,

protective immune response in humans has been challenging
[R. L. Burke, *Current Status of HSV Vaccine Development*, in
The Human Herpesviruses, 367-379, (B. Roizman, R. J.
Whitley and C. Lopez, eds. 1993)]. Live virus vaccines
5 have the risk of establishing latency and reactivating.
Live virus vaccines also have the potential of recombining
with natural isolates.

Attenuated recombinant viruses and subunit vaccines
have been investigated to avoid these risks. Meignier et
10 al describe a recombinant virus resulting from the removal
of a region of herpes simplex virus type 1 (HSV-1) required
for virulence and the insertion of herpes simplex virus
type 2 (HSV-2) glycoprotein genes [J. Infect. Dis.,
158:602-614 (1988)]. The viruses had reduced pathogenicity
15 and induced immunity in a number of animal models.

More recently, recombinant herpes simplex viruses with
deletions in essential immediate early or early genes have
been described. These recombinant viruses are described as
being efficacious in inducing immunity and reducing acute
20 replication and establishment of latency of the challenged
wild-type virus in mice. Nguyen et al describe
replication-defective mutants of HSV-1 that have mutations
in the essential genes encoding infected cell protein 8
("ICP8") or ICP27 [J. Virol. 66:7067-7072 (1992)]. The
25 ICP8 mutant (Δ 301) expresses the products of the α and β
genes while the ICP27 mutant (Δ 504) expresses the products
of the α , β , and γ_1 genes in the cells that the viruses can
infect. Both viruses induced antibody responses that were
lower than parental (KOS 1.1) virus, but the level induced
30 by the ICP27 mutant was higher than that induced by
infection with the ICP8 mutant. Morrison and Knipe later
demonstrated that injection of these viruses protected mice
against development of encephalitis and keratitis, and
decreased the primary replication of virulent challenge

virus [J. Virol. 68:689-696 (1994)]. WO95/18852 describes similar replication-defective herpesvirus mutants and WO94/03207 describes vaccines based on these mutants.

Another recombinant virus has been described that has
5 a deletion in the glycoprotein H (gH) coding region
[Forrester et al, J. Virol. 66:341-348 (1992);
WO92/05263]. This virus forms virions after infection of
non-helper cells, but the viruses fail to infect in a
subsequent round. Inoculation of mice with the gH deletion
10 virus resulted in a more rapid clearance of the wild-type
challenge virus compared to vaccination with chemically-
inactivated virus [Farrell et al, J. Virol. 68:927-932
(1994)]. Inoculation of guinea pigs with the gH deleted
recombinant virus resulted in reduced primary vaginal
15 disease and reduced recurrences [McLean et al, J. Infect.
Dis. 170:1100-1109 (1994)].

Most viruses encode proteinases that function in the
processing of viral proteins during infection [W. G.
Dougherty and B. L. Semler, Microbiological Reviews,
20 57:781-822 (1993)]. Biological and biochemical studies
have shown that HSV-1 possesses a proteinase that can
process another viral protein, the capsid assembly protein
(also known as p40, ICP35 and VP22a). Similar proteinases
are encoded in the genome of other members of the
25 Herpesviridae. This family of DNA viruses includes HSV-1,
HSV-2, human and simian cytomegalovirus (HCMV, SCMV),
varicella-zoster virus (VZV), Epstein-Barr virus (EBV),
human herpesvirus types -6, -7, and -8 (HHV-6, HHV-7, and
HHV-8), pseudorabies virus (PRV), bovine herpesvirus (BHV),
30 equine herpesvirus (EHV), and rhinotracheitis virus, among
others.

Early work by Preston et al, [J. Virol. 45:1056-1064
(1983)] showed that a temperature-sensitive (ts) mutant in
HSV-1 (ts1201) failed to cleave the capsid assembly protein
35 to its lower molecular weight forms at the nonpermissive

temperature. This mutant also failed to package viral DNA. By marker rescue, the defect was mapped to a region of the genome in what is now known as the UL26 open reading frame (ORF) [McGeoch et al, J. Gen. Virol. 69:1531-1574 (1988)].

5 Subsequent analysis showed that two transcripts initiate in the UL26 region, a primary transcript of about 2.1 kb which encodes a protein of 635 amino acids, and a more abundant transcript which is initiated within the UL26 ORF, about 1000 nucleotides 3' of the primary transcript initiation.

10 This smaller transcript encodes a predicted protein of 329 amino acids and is 3' coterminal with the larger 80 kDa ORF encoded by the larger transcript [F. Y. Liu and B. Roizman. J. Virol. 65:206-212 (1991)]. The defect in the ts1201 mutant maps in the 5' region of the longer transcript which

15 has been shown to encode a proteinase activity in HSV-1 [F. Y. Liu and B. Roizman. J. Virol. 65:5149-5156 (1991)] or in simian cytomegalovirus [Welch et al, Proc. Natl. Acad. Sci. USA. 88:10792-10796 (1991)].

Superinfection/transient expression [F. Y. Liu and B. Roizman. J. Virol. 65:5149-5156 (1991)], transient

20 expression [Welch et al, Proc. Natl. Acad. Sci. USA. 88:10792-10796 (1991)], and infection [Preston et al, Virol. 186:87-98 (1992)] studies with the protease domain and the capsid assembly protein domain showed that the

25 proteinase cleaves the capsid assembly protein near its carboxyl terminus. Further studies with the proteins produced in *E. coli* confirmed that the full-length protein of the UL26 ORF is capable of cleaving itself at two sites as well as cleaving the capsid assembly protein [Deckman et

30 al, J. Virol. 66:7362-7367 (1992)]. DiIanni et al later located the cleavage sites between amino acids 247/248 and 610/611 of the UL26 ORF [J. Biol. Chem. 268:2048-2051 (1993)].

Although the results with ts1201 suggest that the

35 defect in the virus is in its ability to cleave the capsid

assembly protein and subsequent encapsidation of DNA, it is not known whether this phenotype is the result of a defect in the protease activity *per se*, or whether the 5' region of the UL26 ORF encodes some other functions required for capsid assembly and maturation. The processed proteinase domain of the 80 kDa precursor (designated as "VP24" or "N_O") has been identified in B-capsids [Davison et al, J. Gen. Virol. 73:2709-2713 (1992)] and is retained in A-capsids and C-capsids [F. J. Rixon, *Structure and Assembly of Herpesviruses*, in *Seminars in Virology*, vol. 4, 135-144, (A. J. Davison, ed. 1993)] suggesting a structural role for this domain. B-capsids are immature capsids in the nucleus of the infected cell that contain the capsid assembly protein, but not viral DNA. These capsids are thought to be the precursors of A-capsids which fail to package DNA and C-capsids which package DNA with concomitant loss of the capsid assembly protein [B. Roizman and A. Sears, *Herpes Simplex Viruses and Their Replication*, in *Human Herpesviruses*, 11-68, (B. Roizman, R. J. Whitley, and C. Lopez, eds. 1993)]. Gao et al constructed and characterized a null mutant virus ("m100") that contains a deletion within the protease domain of the HSV-1 UL26 gene [J. Virol. 68:3702-3712 (1994)]. The mutant virus could be propagated on a complementing cell line but not on noncomplementing Vero cells, indicating that the protease domain of UL26 is essential for viral replication in cell culture. DNA replication occurred at near wild-type levels, but the viral DNA was not processed to unit genome length or encapsidated.

We have generated a recombinant virus to further investigate the role of this domain with respect *in vivo* effects. The recombinant virus is avirulent *in vivo* and induces immunity to challenge by wild-type HSV-1.

35

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the construction of four plasmids. (A) Plasmid pMON15839a contains a 3.4 kb *KpnI* fragment of HSV-1 ("KOS") upstream of the SV40 polyadenylation signal. (B) Plasmid pMON15840 has a UL26 ORF downstream of the herpesvirus ICP6 promoter region. Translation of UL26 begins at methionine 10. (C) Sequence of the multiple cloning site inserted into the *BspEI/BclI*-digested pMON27005. (D) Plasmid pMON15835 contains an ICP6- β -glucuronidase cassette inserted into the *BclI* site of pMON27005. The UL26 ORF is shown as the stippled box, the ICP6 promoter region is shown as the hatched box. The plasmids are not drawn to scale. Abbreviations: "K", *KpnI*; "B", *BspEI*; "S", *SmaI*.

Figure 2 shows the Southern blot analysis of recombinant viruses. Viral DNA was digested with *NotI* or *KpnI*, transferred to nitrocellulose and hybridized to an α -³²P-dGTP-labeled 3.4 kb *KpnI* fragment shown in Figure 1A. Schematics show the restriction maps of the viruses. The hatched region in the UL26 deletion schematic is the ICP6- β -glucuronidase insertion in the protease domain. Lane 1, HSV-1 ("17"); Lane 2, HSV/UL26/ β -gluc; Lane 3, HSV/UL26/res. Abbreviations: "N", *NotI*; "K", *KpnI*.

Figure 3 is a graphical representation which shows the multistep growth curves of mutant viruses. BHK/UL26 helper or BHK/C2 cells were infected at an MOI of 0.1. Cells were harvested at various time points and the virus was titered on BHK/UL26 helper cells. Circles represent virus from BHK/UL26 helper cells and squares represent virus from BHK/C2 cells. The error bars represent the ranges of duplicate determinations.

Figure 4 shows the capsid assembly protein processing results. BHK/C2 and BHK/UL26 helper cells were infected with an MOI of 5 for 18 hours. Cells were harvested and

proteins were separated on a 14% denaturing SDS-polyacrylamide gel, transferred to Immobilon membrane, and probed with antisera generated against a peptide of the HSV-1 capsid assembly protein (HSVAs-414). The open star indicates the major unprocessed assembly protein and the closed star indicates the processed form. Lane 1, mock infected cells; Lane 2, wild-type HSV-1; Lane 3, HSV/UL26/ β -gluc; Lane 4, HSV/UL26/res.

Figure 5 is a graphical representation which shows the viral challenge of mice. Mice were inoculated intraperitoneal (i.p.) with 6×10^5 pfu of each virus and scored for mortality. The survivors and control mice (age- and sex-matched) were challenged with another dose of wild-type virus on day 32.

Figure 6 is a graphical representation which shows i.p. or subcutaneous (s.q.) inoculation of mice inoculated with media or 10^2 , 10^4 , or 10^6 pfu of HSV/UL26/ β -gluc. Mice were inoculated on day 1 either i.p. (A) or s.q. (B). On day 31 the mice were challenged with 10^7 pfu of wild-type HSV-1 given i.p.

DESCRIPTION OF THE INVENTION

The present invention describes a vaccine comprising an assembly-deficient herpesvirus. Preferably, the herpesvirus contains an inactivated form of an essential protease gene. More preferably, the protease is required for the processing and assembly of immature, noninfectious capsid particles into mature, infectious capsid particles.

The protease gene can be inactivated by a method selected from deletion, insertion, substitution and any combination of deletion, insertion, or substitution. Preferably, the protease gene is inactivated by deletion of viral DNA and insertion or substitution of nonviral (heterologous) DNA. More preferably, the essential

protease gene is inactivated by deletion of viral DNA and insertion of nonviral (heterologous) DNA.

Preferably, the inactivated protease gene is selected from HSV-1 UL26, HSV-2 UL26, and HCMV UL80. More

5 preferably, the protease is encoded by HSV-1 UL26.

The invention includes herpesviruses selected from HSV-1, HSV-2, HCMV, SCMV, VZV, EBV, HHV-6, HHV-7, HHV-8, PRV, BHV and EHV. Preferably, the virus is HSV-1 or HSV-2.

More preferably, the virus is HSV-1. Preferably, the
10 vaccine comprises the assembly-deficient mutant virus designated HSV/UL26/ β -gluc.

Preferably, the vaccine comprises a dose between about 10 and about 10^6 plaque-forming units of said assembly-deficient herpesvirus.

15 Additionally, the present invention describes a method of manufacturing a vaccine comprising an assembly-deficient herpesvirus, by preparing stocks of the virus in a recombinant cell line capable of generating properly assembled virus. Preferably, the method of manufacturing a
20 vaccine uses a virus selected from HSV-1, HSV-2, HCMV, SCMV, VZV, EBV, HHV-6, HHV-7, HHV-8, PRV, BHV, and EHV. More preferably, the method of manufacturing a vaccine uses virus selected from HSV-1 and HSV-2. Even more preferably, the method of manufacturing a vaccine uses a virus derived
25 from HSV-1.

The present invention also describes a use of an assembly-deficient herpesvirus in a preparation of a vaccine.

Additionally, the present invention describes a method
30 of immunizing a susceptible mammal against a herpesvirus by administering a vaccine comprising an assembly-deficient herpesvirus. Preferably, the susceptible mammal is selected from human, monkey, cow, horse, sheep, and pig. More preferably, the mammal is human.

35 The present invention also describes a mutant

herpesvirus containing an inactivated form of an essential protease gene required for the processing and assembly of immature, noninfectious capsid particles into mature, infectious capsid particles, said essential protease gene
5 is inactivated by deletion of viral DNA and insertion of nonviral (heterologous) DNA.

Preferably, the essential protease gene is inactivated by deletion of a portion of the essential protease gene and insertion of a nonviral (heterologous) DNA segment
10 comprising a reporter gene under the control of an inducible promoter. More preferably, the essential protease gene is the HSV-1 UL26 gene. More preferably, the inducible promoter is the HSV-1 ICP6 (UL39) promoter. Even more preferably, the nonviral (heterologus) DNA segment
15 comprises the gusA gene encoding E. coli beta-glucuronidase under the control of an HSV-1 ICP6 (UL39) promoter.

The present invention additionally describes a recombinant host cell line expressing an essential protease gene under the control of an inducible promoter.
20 Preferably, the recombinant host cell line is derived from a mammalian source. More preferably, the recombinant host cell line is derived from a rodent source. Even more preferably, the recombinant host cell line is BHK-21. Preferably, the inducible promoter is a herpesvirus
25 promoter. More preferably, the inducible promoter is the HSV-1 ICP6 (UL39) promoter.

The present invention also describes a method of making mutant herpesviruses by introducing the virus into a recombinant host cell line and recovering mature viral
30 particles harboring the mutant viral genome.

Definitions

The phrase "assembly-deficient" is intended to mean that the virus is able to replicate its DNA, but is unable
35 to complete the steps of cleaving that DNA into genome-

length pieces and packaging that DNA into viral capsids.

The phrase "mature virion" is intended to mean a viral particle capable of infection in a susceptible host or cell type. The phrase "nonviral (heterologous) DNA" is intended to mean DNA that is not derived from a herpesvirus genome. The phrase "nonessential gene" is intended to mean a gene that can be disrupted by deletion, insertion, substitution, or a combination of deletion, substitution, and insertion of other DNA, and that a recombinant virus containing this disrupted gene can propagate in cultured cells that do not express nondisrupted copies of the same gene. The phrase "essential gene" is intended to mean a gene that is not a nonessential gene. The phrase "essential viral protease gene" is intended to mean an essential viral gene that encodes a protease.

EXPERIMENTAL

Baby hamster kidney cells (BHK-21) were obtained from American Type Culture Collection (ATCC) (Rockville, MD) and were cultured in Dulbecco's modified Eagle's media supplemented with 10% fetal bovine sera (JRH Biosciences, Lenexa, KS), 2 mM additional L-glutamine (JRH Biosciences) and 100 µg-units/ml of penicillin-streptomycin (JRH Biosciences). HSV-2 strain MS was obtained from ATCC and HSV-1 strain 17 was obtained from Dr. R. Lausch, University of South Alabama. Viral DNA was isolated and purified according to D'Aquila and Summers [J. Virol. 61:1291-1295 (1987)] for stock quantities and according to DeLuca et al [J. Virol. 52:767-776 (1984)] and Rader et al [J. Gen. Virol. 74:1858-1869 (1993)] for rapid Southern blot evaluation.

To generate cell lines that complement the defect in the UL26 gene, BHK-21 cells were cotransfected with 10 µg plasmid DNA containing the complementing sequences (see below) and 1 µg

SV2neo [P. J. Southern and P. Berg. J. Mol. Appl. Genet. 1:327-341 (1982)] using LipofectAmine Reagent (GIBCO/BRL/Life Technologies, Inc., Grand Island, NY) according to the manufacturer's instructions. After two days, cells were treated
5 with trypsin and diluted into media containing 400 µg/ml G418 (Geneticin, Gibco/BRL/Life Technologies, Inc.). Individual colonies were isolated and expanded for determination of helper function.

Two plasmids were made for engineering a cell line
10 that would complement a protease defective HSV-1. First, a 3.4 kb *KpnI* fragment from HSV-1 (KOS) (from P. Olivo, Washington University) containing the entire UL26 promoter region and open reading frame (ORF) was subcloned into the *KpnI* site of pMON3327 [Highkin et al, Poultry Science
15 70:970-981 (1991)] such that the SV40 polyadenylation signal is 3' to the UL26 ORF. This plasmid was designated pMON15831a (Figure 1). The second plasmid consists of the UL26 ORF under control of the HSV-1 ICP6 (UL39) promoter region. This plasmid was synthesized in several steps.
20 First, the 320 bp *SmaI* fragment containing the 5' end of the UL26 ORF starting at nucleotide 18 was subcloned into the *SmaI* site of pUC18 resulting in pMON15838. The 1642 bp *BsgI-KpnI* fragment from pMON27010 was inserted into *BsgI-KpnI* digested pMON15838 to yield pMON15839. pMON27010 has
25 the 3.4 kb *KpnI* fragment from HSV-1 (strain 17) in pUC18. The 1956 bp *EcoRI-HindIII* fragment was isolated from pMON15839 and the ends were filled-in using Klenow polymerase before ligating to pMON15834 which had been digested with *BamHI* and filled in as above. The resulting
30 plasmid was designated pMON15840 (Figure 1). Plasmid pMON15834 has the filled-in 633 bp *XhoI-SnaBI* fragment of HSV-1 (strain 17) that directs the expression of the ICP6 ORF in the *SmaI* site of pMON3327.

A β -glucuronidase cassette was inserted into the UL26
35 ORF as follows: The β -glucuronidase cassette under control

of the HSV-1 ICP6 promoter region was constructed by isolating a 633 bp *XhoI*-*SnaBI* fragment from pMON27002. pMON27002 has the 16,191 bp *Sse8387I* D fragment from HSV-1 (strain 17) in pNEB193 (New England Biolabs, Beverly, MA).

5 The *XhoI* site was filled-in using Klenow polymerase and was ligated into the filled-in *NcoI* site in pMON14327 (Luckow et al, J. Virol. 67:4566-4579 (1993)) which contains the β -glucuronidase gene. The new plasmid is designated pMON15833 (Figure 1). The *NotI* H fragment (6542 bp)

10 containing the HSV-1 (strain 17) UL26 ORF was subcloned into *NotI*-digested pBS2SKP (Stratagene, La Jolla, CA) to generate plasmid pMON27005. pMON27005 was digested with *BspEI* and *BclI*. A polylinker containing multiple cloning sites and complementary ends was inserted to create plasmid

15 pMON27026 (Figure 1). To construct a cassette for recombination with wild-type HSV-1 (strain 17), the 2871 bp ICP6- β -glucuronidase sequences were removed from pMON15833 by *BamHI* digestion and ligated into *BclI*-digested pMON27026. The new vector is designated pMON15835 (Figure

20 1).

BHK cells were seeded at 4×10^5 cells per 60 mm dish one day prior to transfection. One microgram of genomic viral DNA and an equimolar amount of linearized plasmid containing the desired sequence changes were mixed with 25

25 μ g of LipofectAmine in OptiMem media (Gibco/BRL/Life Technologies) and added to the cells for 4 hours. The media was aspirated and replaced by growth media. The transfected cells were completely lysed before the harvesting of the supernatant. Clarified, serially-diluted

30 supernatant (0.8 ml) was plated onto the helper cell line in 60 mm dishes at 37 °C for 60 minutes. The inoculum was removed and the cells were overlaid with a 1% agarose (JRH Biosciences)/10% FBS/EMEM (Biowhitaker, Walkersville, MD). After the formation of visible cytopathic effects, 4 ml

35 Dulbecco's phosphate-buffered saline (JRH Biosciences)

containing 300 µg/ml X-gluc (BioSynth AG, Switzerland) and 80 µg/ml neutral red (Sigma, St. Louis, MO) were added, and plaques were picked using a Pasteur pipette. For viruses containing the β -glucuronidase gene, blue plaques were selected. For rescued viruses (see below), clear plaques were selected. The viruses were plaque-purified three times or purified by limiting dilution. Purified virus was isolated and the DNA was analyzed by restriction enzyme analysis and Southern blotting [Maniatis et al, Molecular Cloning, A Laboratory Manual (1982)].

Analysis of the clear plaque virus in the blue plaque virus stock was done by the polymerase chain reaction (PCR) (Saiki et al, Science. 239:487-491 (1988)]. Two oligonucleotides that flanked the unique BsgI site in the HSV-1 (strain 17) UL26 ORF were synthesized (Genosys, The Woodlands, TX). The forward primer was identical to nucleotides 50,913 to 50,932 of the HSV genome [5'-GGGCGAGTTGGCATTGGATC-3', McGeoch et al, J. Gen. Virol. 69:1531-1574 (1988)]. The reverse primer was complementary to sequences 51,195 to 51,175 of the HSV-1 genome (5'-AGACCGAGGGCAGGTAGTT-3'). Virus was extracted with phenol:chloroform and the viral DNA was ethanol-precipitated. The PCR was carried out using the GeneAmp PCR kit (Perkin-Elmer-Cetus, Norwalk, CT). The reaction products were analyzed on 5% polyacrylamide gels.

Peptide antibodies were raised in rabbits against regions corresponding to amino acids 414 through 428. Peptide HSVAs-414 (C-PAAGDPGVRGSGKR) was synthesized by Chiron Mimotopes Pty. Ltd. (Raleigh, NC) and purified to greater than 95% purity. HSVAs-414 mapped to the central region of the capsid assembly region of the UL26 and UL26.5 genes. The peptide had a free acid at the C-terminus and was conjugated to diphtheria toxoid at the N-terminus. Rabbits were inoculated with 100 µl of 1 µg/ml of protein mixed with an equal volume of Freund's complete adjuvant,

boosted with the same material in Freund's incomplete adjuvant at 4 week intervals beginning at week 2, and bled 10 and 17 days after boosting.

Cells were seeded in wells of six-well dishes at 5 x 10⁵ cells/well. The next day, cells were infected with a multiplicity of infection (MOI) of 5 pfu/cell for 60 minutes at 37 °C with occasional gentle rocking. The inoculum was aspirated and growth media was added. At 18 hours post infection, the media was aspirated and 400 µl of 1X Protein Disruption Buffer (Novex, San Diego, CA) containing 10% β-mercaptoethanol were added. Proteins were separated on 14% Tris-glycine SDS-polyacrylamide gels (Novex) for 1.5 hours at 125 volts. The gels were incubated for 10 minutes in 1X Transfer Buffer (Novex) and blotted to Immobilon-P membranes (Novex) for 1-2 hours at 30 volts. The membranes were incubated in 1X Tris-buffered saline containing Tween 80 (TTBS), supplemented with 5% powdered milk for at least one hour (typically overnight). The blot was rinsed twice with TTBS for 15 minutes, and incubated with primary antibody for 1 hour at a dilution of 1/1000. The blot was rinsed twice with TTBS for 15 minutes before incubating with secondary antibody (alkaline phosphatase conjugated goat anti-rabbit antibody, Promega, Madison, WI) for 1 hour at a dilution of 1/4000. The alkaline phosphatase was visualized by incubating the blot in nitro blue tetrazolium (NBT)/5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Promega) for 5 to 15 minutes, and the reaction stopped by rinsing extensively in H₂O.

Viral replication was examined by multistep growth analysis on the BHK/UL26 helper line and on BHK cells that did not contain the helper function but were G418-resistant (BHK/C2). Cells (1 x 10⁵) were seeded in wells of a 24-well plate and infected with an MOI of 0.1 plaque-forming-units (pfu) per cell. At various times post infection, the infected cells were subjected to three rounds of freeze-

thawing [Tengelsen et al, J. Virol. 67:3470-3480 (1993)] and the-lysates were titered on the BHK/UL26 helper line.

To generate cell lines capable of supporting replication recombinant viruses with a deletion and
5 insertion within the UL26 open reading frame, BHK cells were cotransfected with pMON15831a which has the 3.4 kb KpnI fragment of HSV-1 (KOS) 5' to the SV40 polyadenylation signal (Figure 1) and SV2neo. G418-resistant cells were isolated and shown by Southern blot analysis to contain the
10 HSV-1 KpnI fragment. To determine which cell line would express the UL26 gene products, the cell lines were infected with HSV-2 (MS) to stimulate the UL26 promoter in the cell. HSV-1-specific anti-peptide antisera, generated by inoculating rabbits with the peptide HSVAs-414
15 conjugated to diphtheria toxin, was used to identify expression of the cellular UL26 gene products (data not shown). This cell line, designated BHK/UL26/8, was used for generation of recombinant viruses. A G418-resistant cell line which was cotransfected with pMON3327 and SV2neo
20 serves as a control and is designated BHK/C2. An additional helper cell line (BHK/UL26 helper) was isolated after the discovery that significant amounts of rescued virus were being generated due to recombination with the KpnI fragment present in BHK/UL26/8. This second line was
25 transfected with plasmid pMON15840 which has the UL26 ORF behind the ICP6 promoter and lacks the large amount of HSV DNA 5' to the UL26 ORF contained in pMON15831a. Translation from this integrated plasmid began at the methionine at the natural amino acid 10. Candidate cell
30 lines were screened for their ability to support growth of the blue plaque phenotype recombinant virus (see below). A cell line isolated from this latter screening that supports the growth of the UL26 mutant virus was designated the BHK/UL26 helper cell line.

35 Cell line BHK/UL26/8 was transfected with HSV-1

(strain 17) genomic DNA and plasmid pMON15835 which contains a *NotI* fragment of HSV-1 (strain 17) with a deletion in the protease domain of the UL26 ORF and an insertion of the bacterial β -glucuronidase gene under control of the HSV-1 (strain 17) ICP6 promoter (Figure 1). After cell lysis, the supernatant was serially-diluted on BHK/UL26/8 and blue plaques were identified after 4 to 5 days post infection. The blue plaques were picked and plaque-purified three times. The recombinant virus was designated HSV/UL26/ β -gluc. Plaque purification indicated poor segregation between the blue phenotype recombinant virus and a clear plaque phenotype virus which appeared to have a growth advantage, even on the helper cell line.

To determine the genotype and source of the clear plaque virus, DNA amplification was performed on cell-free viral DNA from the mixed culture of blue and clear plaque phenotype viruses. Amplification of a 283 bp fragment indicated the presence of wild-type virus in the stock. The PCR product was digested with *BsgI*, which cuts the fragment from wild-type (strain 17) DNA, but does not cut the fragment from wild-type (strain KOS) DNA, which is the source of DNA in the helper cell (data not shown). Lack of digestion of the PCR product by *BsgI* indicated that the wild-type virus was actually a revertant generated by recombination between the blue plaque phenotype virus and the UL26 sequences in the helper cell line. The rescued virus was designated HSV/UL26/res.

In order to generate a more pure stock of HSV/UL26/ β -gluc, a new helper cell line (BHK/UL26 helper) was isolated in which the amount of HSV DNA sequence 5' to the UL26 ORF was eliminated and replaced with the ICP6 promoter region fragment (pMON15840, Figure 1). Propagation of HSV/UL26/ β -gluc on this cell line resulted in only the blue plaque phenotype.

Viral DNA from wild-type (strain 17), HSV/UL26/ β -gluc

and the rescued virus was digested with *NotI* or *KpnI*. The digested DNA was analyzed by Southern blot analysis after probing with a restriction fragment containing the full length UL26 open reading frame and 5' flanking sequences.

5 The results showed the expected pattern of digestion (Figure 2). Wild-type and rescued virus showed the same pattern as expected with both *NotI* (6.3 kb) and *KpnI* (3.4 kb) digestion (Lanes 1 and 3). Deletion of a small region of the UL26 ORF and insertion of the β -glucuronidase gene

10 resulted in addition of a new *NotI* site (resulting in predicted 4.8 and 4.4 kb fragments) and a new *KpnI* site (resulting in a 4.0 and 2.1 kb fragments) (Lane 2) in HSV/UL26/ β -gluc.

Growth curves were determined for the viruses on the

15 different cell lines. At various times post infection, the cells were harvested and freeze-thawed three times before plating on BHK/UL26 helper cells. The results indicated that HSV/UL26/ β -gluc failed to replicate in BHK/C2 cells but grew with wild-type kinetics on the BHK/UL26 helper

20 cell line. The wild-type (strain 17) HSV-1 and the rescued virus replicated to identical titers and at identical rates on both BHK/C2 and the BHK/UL26 helper cell lines (Figure 3).

Since it has been shown by transient transfection

25 experiments in mammalian cells, bacteria and ts1201 that certain mutations in the 5' region of UL26 fail to cleave the capsid assembly protein [reviewed in Gao et al, J. Virol. 68:3702-3712 (1994)], HSV/UL26/ β -gluc was used to infect BHK/C2, BHK and BHK/UL26 helper cells at an MOI of

30 5. At 18 hours post infection, the cells were lysed in SDS-PAGE sample buffer and proteins separated on a 14% SDS-PAGE gel. After transfer to Immobilon P membranes, the blots were incubated in antisera against the HSV-1 capsid assembly protein. The results are shown in Figure 4.

35 Infection of BHK/C2 cells by HSV/UL26/ β -gluc resulted in a

failure to process the capsid assembly protein to a lower molecular weight form. Infection of BHK/helper cells by HSV/UL26/ β -gluc showed that the capsid assembly protein was appropriately processed. The rescued recombinant virus
5 (HSV/UL26/res) processed the capsid assembly protein in both cell lines as did wild-type HSV-1 (lanes 2 and 4). The capsid assembly protein was made at normal levels during infection in both helper and non-helper cells but is not cleaved in the non-helper cells. The HSV/UL26/ β -gluc
10 recombinant fails to process the capsid assembly protein and has restricted growth.

Female Swiss-Webster mice (12-14 grams, Charles Rivers Laboratories, Wilmington, MA) were inoculated with virus intraperitoneally or subcutaneously with 100 μ l volumes.
15 Subcutaneous inoculations were delivered on the dorsal side near the base of the tail after brief CO₂/O₂ treatment of the mice. Virus was resuspended in DMEM containing 5% FBS unless otherwise noted. Food and water were given *ad libitum*. Mice were euthanized if they became moribund due
20 to paralysis.

Mice were inoculated i.p. with 6×10^5 pfu (as determined on the helper cell line) of either the wild-type (strain 17) HSV, HSV/UL26/ β -gluc, or the rescued virus in a 100 μ l volume. As shown in Figure 5, mice infected with
25 wild-type (strain 17) or the rescued virus died by day 7 post infection. All mice infected with HSV/UL26/ β -gluc survived. The animals that originally received HSV/UL26/ β -gluc were challenged with wild-type HSV-1 (strain 17), i.p., at the same dose given initially. Age- and sex-
30 matched naive mice were also inoculated. One of the HSV/UL26/ β -gluc infected mice was found dead about 16 hours post infection with the wild-type virus. Death was probably not related to the virus since it occurred so quickly after infection. The other 9 mice survived the
35 wild-type virus challenge. The naive mice were susceptible

to wild-type virus infection although it took longer for the virus to cause morbidity and mortality (Figure 5).

In a second experiment, mice were inoculated i.p. with ten-fold serial dilutions of HSV/UL26/ β -gluc starting at the same inoculum used in the initial experiment. On day 39, the mice were challenged i.p. with 6×10^6 pfu of HSV-1 (strain 17). This dose of wild-type virus was 10-fold higher than that in the initial experiment and resulted in 90% death in the mice that were initially inoculated with DMEM/5% FBS (Table 1, mock-infected set). Again, within 16 hours, 6 mice were found dead. Two of these were in the set that were previously inoculated with 10 pfu of HSV/UL26/ β -gluc and 4 were in the set that were previously given 1×10^5 pfu of HSV/UL26/ β -gluc. There was a significant difference among the six survival curves ($p < 0.02$, log rank test). The data suggests that mice that were inoculated with HSV/UL26/ β -gluc survived in a dose-dependent manner (Table 1). The survival curves of the mice receiving the highest dose of HSV/UL26/ β -gluc were statistically different from the mock group ($p = 0.023$, log rank test).

Table 1.

HSV/UL26/ β - gluc	% Survival*
mock	10
6×10^1 pfu	12.5
6×10^2 pfu	30
6×10^3 pfu	60
6×10^4 pfu	50
6×10^5 pfu	83.3

* Survival determined on day 20 after i.p. challenge with 6×10^6 pfu of wild-type HSV-1 (strain 17). $N = 10$ for all groups except for the 6×10^1 ($N = 8$) and 6×10^5 ($N = 6$) due to the early death.

In a third experiment, virus stocks were prepared as previously but were resuspended in DMEM without any FBS. Sets of ten mice were inoculated with DMEM alone or with increasing doses of HSV/UL26/ β -gluc by either i.p. or s.q. routes. After one month, all mice were challenged with 10^7 pfu of wild-type virus by i.p. inoculation. Some controls for rapid death included animals that received i.p. media then challenged with i.p. media, HSV/UL26/ β -gluc and then media or, HSV/UL26/ β -gluc and then challenged with HSV/UL26/ β -gluc. None of these animals died during the course of the experiment. None of the experimental animals died within 24 hours of challenge. Of these, 90 animals had received two inoculations of virus and one would expect about 10-12% to have died rapidly. The results with the experimental groups are shown in Figure 6A and 6B. There was a significant difference among the survival curves for both the i.p. ($p < 0.01$) and s.q. ($p < 0.01$) inoculations (log rank test). Regression analysis shows that there is a dose-dependent effect of HSV/UL26/ β -gluc on survival ($p < 0.05$, Cochran-Armitage test) for both groups.

It is expected that this virus would have reduced efficiency and reactivate poorly, if at all. The fact that the mutation effects a late gene function suggests that the recombinant virus may be more efficacious in inducing immunity than viruses that have deletions in immediate early or early genes. The assembly-defective HSV/UL26/ β -gluc virus is a member of a new class of vaccine candidates with a defect in late gene activity.

It is anticipated that the defect in the essential gene described in an assembly-deficient virus can be incorporated in a virus with other mutations in essential or nonessential genes. Such genes, like ICP47 of HSV-1, may modulate the host's ability to mount an immune reaction to the virus [Hill et al, Nature 375:411-415 (1995); Fröh

et al, Nature 375:415-417 (1995)].

The vaccines of the present invention can be of a lyophilized form or suspended in a pharmaceutically-acceptable carrier. Suitable suspensions can include
5 phosphate buffer, saline, glucose, inactivated serum, excipients, and adjuvants. The vaccine can be prepared and used according to standard techniques well known in the art [reviewed in R. L. Burke, Seminars in Virology, 4:187-197, (1993)]. The effective dose may also be determined by
10 standard techniques well known in the art. Generally, vaccines are formulated in a suitable sterilized buffer and administered by intradermal, intramuscular, or subcutaneous injection at a dosage of between 10^3 and 10^9 pfu/kg. The vaccine can also be formulated for oral or ocular
15 administration in vehicles known in the art.

The foregoing detailed description is given to facilitate clearness of understanding only, and no unnecessary limitations are to be understood therefrom, as modifications within the scope of the invention will be
20 obvious to those skilled in the art.

What is claimed:

1. A vaccine comprising an assembly-deficient herpesvirus.
2. The vaccine of Claim 1 wherein said
5 herpesvirus contains an inactivated form of an essential protease gene.
3. The vaccine of Claim 2 wherein said essential protease gene is required for the processing and assembly of immature, noninfectious capsid particles
10 into mature, infectious capsid particles.
4. The vaccine of Claim 1 wherein said herpesvirus is selected from HSV-1, HSV-2, HCMV, SCMV, VZV, EBV, HHV-6, HHV-7, HHV-8, PRV, BHV and EHV.
5. The vaccine of Claim 4 wherein said
15 herpesvirus is HSV-1 or HSV-2.
6. The vaccine of Claim 4 wherein said herpesvirus is HSV-1.
7. The vaccine of Claim 3 wherein said essential protease gene is selected from HSV-1 UL26, HSV-2 UL26,
20 and HCMV UL80.
8. The vaccine of Claim 7 wherein said essential protease gene is HSV-1 UL26.
9. The vaccine of Claim 2 wherein said essential protease gene is inactivated by a method selected from
25 deletion, insertion, substitution of DNA, and any combination of deletion, insertion, or substitution of DNA.
10. The vaccine of Claim 9 wherein said essential protease gene is inactivated by deletion of viral DNA
30 and insertion of nonviral (heterologous) DNA.

11. The vaccine of Claim 1 comprising between about 10^5 and about 10^6 plaque-forming units of said herpesvirus.

12. The vaccine of Claim 1 wherein said assembly-deficient herpesvirus comprises the strain designated HSV/UL26/ β -gluc.

13. A method of manufacturing a vaccine of Claim 1 comprising an assembly-deficient herpesvirus, by preparing stocks of said herpesvirus in a recombinant cell line capable of generating properly-assembled virus, and suspending said virus in a pharmaceutically-acceptable carrier.

14. The method of manufacturing a vaccine of Claim 13 wherein said essential protease gene is an HSV-1 UL26 gene.

15. The method of Claim 13 wherein said vaccine comprises the strain HSV/UL26/ β -gluc.

16. The method of Claim 13 wherein said cell line is mammalian.

17. The method of Claim 16 wherein said cell line supports replication of said herpesvirus.

18. The method of Claim 17 wherein said cell line is the cell line designated BHK/UL26/8.

19. The method of Claim 17 wherein said cell line comprises the cell line designated BHK/UL26 helper.

20. A use of an assembly-deficient herpesvirus in a preparation of a vaccine.

21. A method of immunizing a mammal against a herpesvirus by administering a vaccine of Claim 1 in a pharmaceutically-acceptable carrier.

22. The method of Claim 21 where the mammal is selected from human, monkey, cow, horse, sheep and pig.

23. The method of Claim 22 where the mammal is human.

5 24. A mutant herpesvirus containing an inactivated form of an essential protease gene required for the processing and assembly of immature, noninfectious capsid particles into mature, infectious capsid particles, with said essential protease gene
10 inactivated by deletion of viral DNA and insertion of nonviral (heterologous) DNA.

25. A mutant virus according to Claim 24 wherein said virus is selected from HSV-1, HSV-2, HCMV, SCMV, VZV, EBV, HHV-6, HHV-7, HHV-8, PRV, BHV and EHV.

15 26. A mutant virus of Claim 25 wherein said essential protease gene is HSV-1 UL26.

27. A mutant virus of Claim 24 wherein a portion of said essential protease gene is deleted and replaced by a nonviral (heterologous) DNA segment comprising a
20 reporter gene under the control of an inducible herpesvirus HSV-1 promoter.

28. A mutant virus of Claim 27 wherein said reporter gene is selected from gusA encoding beta-glucuronidase, lacZ encoding beta-galactosidase, phoA
25 encoding alkaline phosphatase, gfp encoding green fluorescent protein, and aeq encoding aequorin.

29. A mutant virus of Claim 28 wherein said reporter gene is the gusA gene encoding E. coli beta-glucuronidase.

30 30. A mutant virus of Claim 27 wherein said inducible herpesvirus promoter is the HSV-1 ICP6 (UL39) promoter.

31. A recombinant host cell line expressing an essential herpesvirus protease gene under the control of an inducible non-protease promoter.

32. A recombinant host cell line of Claim 31,
5 wherein said host cell line is from a rodent source.

33. A recombinant host cell line of Claim 32,
wherein said host cell line is BHK-21.

34. A recombinant host cell line of Claim 31
wherein said inducible non-protease promoter is the
10 HSV-1 ICP6 (UL39) promoter.

35. A method of making mutant herpesviruses of Claim 24 by introducing said virus into a recombinant host cell line and recovering mature viral particles harboring the mutant viral genome.

15




Fig. 1




Fig. 2





Fig. 3



1 = Mock
 2 = HSV-1 (17)
 3 = HSV/UL26/ β -gluc
 4 = HSV/UL26/res
 M = MW_r Markers

Fig. 4




Fig. 5




Fig. 6A




Fig. 6B

INTERNATIONAL SEARCH REPORT

National Application No.

PCT/US 97/14192

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K39/245 C12N15/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 96 38551 A (MERCK & CO. INC.) 5 December 1996 see page 1, line 18 - page 2, line 2 see page 6, line 1 - line 6 see page 8, line 18 - line 22 see page 8, line 29 - page 9, line 10 see page 23, line 18 - line 23 ---	24-26, 31,35
X	WO 92 13943 A (SMITHKLINE BEECHAM BIOLOGICALS S.A.) 20 August 1992	1-14,16, 17,20-23
Y	see page 5, line 34 - page 6, line 7; claim 11; example 6 --- -/--	15,18, 19,24-35



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 March 1998

Date of mailing of the international search report

27. 03. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Olsen, L

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/14192

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	M.F. AL-KOBAISI ET AL.: "The Herpes simplex virus UL33 gene product is required for the assembly of full capsids" VIROLOGY, vol. 180, 1991, pages 380-388, XP002057787 see the whole document	1-35
Y	--- D.R. THOMSEN ET AL.: "Assembly of the Herpes simplex virus capsid: requirement for the carboxyl-terminal twenty-five amino acids of the proteins encoded by the UL26 and UL26.5 genes" JOURNAL OF VIROLOGY, vol. 69, 1995, pages 3690-3703, XP002057788 see the whole document	1-35
X	--- WO 96 12007 A (MERCK & CO. INC.) 25 April 1996 see claim 4; example 1 -----	31

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/14192

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9638551 A	05-12-96	NONE	
WO 9213943 A	20-08-92	AU 657731 B	23-03-95
		AU 1182992 A	07-09-92
		CA 2101639 A	01-08-92
		EP 0571410 A	01-12-93
		JP 6507066 T	11-08-94
		NZ 241476 A	23-12-93
		NZ 245842 A	23-12-93
WO 9612007 A	25-04-96	AU 3952895 A	06-05-96